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ABSTRACT
CONTEXT AND OBJECTIVE: Cardiac resynchronization therapy (CRT) has emerged as the predominant electrical treatment strategy for patients on 
pharmacological therapy who present heart failure with wide QRS and low ejection fraction. The objective of this study was to investigate whether cardiac 
resynchronization therapy improved mortality and morbidity among patients with heart failure.
METHODS: This was a systematic review using the Cochrane Collaboration’s methodology. The online search strategy included the Cochrane Library, 
Medline (Medical Literature Analysis and Retrieval System Online), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde) and cardiology 
congresses from 1990 to 2006. The criteria for considering studies for this review were as follows:-types of studies: randomized controlled trials; types of 
interventions: cardiac resynchronization therapy compared with other therapies; types of participants: patients with heart failure with low ejection fraction 
and wide QRS; outcomes: death or hospitalization. 
RESULTS: Seven trials met the selection criteria. The risk of death due to congestive heart failure was nonsignificant: relative risk (RR), 0.79; 95% 
confidence interval (CI): 0.60 to 1.03. There was an absolute risk reduction of 4% in all-cause mortality for the experimental group [RR 0.70; CI: 0.60 to 
0.83; number needed to treat (NNT) 25]; sudden cardiac death showed a statistically significant difference favoring the experimental group, with absolute 
risk reduction of 1% (CI: 0.46 to 0.96; RR 0.67; NNT 100). There was an absolute risk reduction of 9% for hospitalization due to heart failure (RR 0.64; 
CI: 0.50 to 0.80; NNT 11) in the experimental group. 
CONCLUSIONS: Patients receiving CRT had a significantly lower risk of hospitalization due to heart failure, but death rates due to heart failure were 
similar.
RESUMO
CONTEXTO E OBJETIVO: A terapia de ressincronização cardíaca (TRC) surgiu como a estratégia de tratamento elétrico predominante para pacientes com 
insuficiência cardíaca com QRS largo e baixa fração de ejeção. O objetivo foi investigar se a terapia de ressincronização cardíaca melhora a mortalidade 
e morbidade dos pacientes com insuficiência cardíaca.  
MÉTODOS: Esta é uma revisão sistemática que utilizou a metodologia da Colaboração Cochrane. A estratégia de busca eletrônica incluiu a Biblioteca 
Cochrane, Medline, Lilacs e congressos de cardiologia de 1990 a 2006. Os critérios de inclusão foram os seguintes: tipos de estudos: estudos clínicos 
randomizados; tipos de intervenções: terapia de ressincronização cardíaca comparada com outras terapias; tipos de participantes: pacientes com 
insuficiência cardíaca com baixa fração de ejeção e QRS largo; desfechos: mortalidade, hospitalização.   
RESULTADOS: Sete estudos foram incluídos. O risco de morte devida à insuficiência cardíaca congestiva foi insignificante: risco relativo (RR) = 0.79; 
intervalo de confiança (IC) de 95% = 0.60 a 1.03; houve redução de 4% do risco absoluto de mortalidade por todas as causas no grupo experimental 
[RR 0.70; IC: 0.60 a 0.83; número necessário para tratar (NNT) = 25]; morte cardíaca súbita mostrou ter diferença estatisticamente significante 
favorável ao grupo experimental, com redução de 1% do risco absoluto (IC: 0.46 a 0.96; RR 0.67; NNT= 100). Houve redução de 9% do risco absoluto 
de hospitalização devido a insuficiência cardíaca (RR 0.64; IC: 0.50 a 0.80; NNT =11) no grupo experimental.
CONCLUSÕES: Pacientes em TRC tiveram risco de hospitalização por falência cardíaca significativamente mais baixo, mas os índices de mortalidade por 
insuficiência cardíaca foram semelhantes.
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INTRODUCTION
Although pharmacological therapies for congestive heart failure 
(CHF) have advanced over recent decades, morbidity and mortality 
have remained high. It is an often-quoted statistic that heart failure af-
fects almost five million people in the United States alone, with about 
500,000 new diagnosed cases per year.1,2 Heart failure is the leading 
cause of hospitalization among patients older than 65 years,3 and it is 
the only form of cardiovascular disease that is still increasing in preva-
lence. For advanced heart failure patients, angiotensin-converting en-
zyme (ACE) inhibitors were the first medication to achieve a reduction 
in mortality of 40% at six months.4 The second choice for pharmaco-
logical treatment of systolic dysfunction is beta-blockers.5 Angiotensin-
receptor blockers have also been shown to reduce a combined outcome 
of morbidity and mortality.6,7 Spironolactone or eplerenone (aldoster-
one blockade) has demonstrated reductions in the relative risk of mor-
tality, of 15% to 30% among patients with NYHA III/IV (New York 
Heart Association classification) and low ejection fraction.8 The non-
pharmacological management consists mainly of lifestyle modification 
such as sodium restriction, and avoidance of non-steroidal anti-inflam-
matory drugs.9-11
In spite of everything, medical therapy and lifestyle modifications 
have been insufficient for treating heart failure patients. Mortality and 
hospitalization rates still need to be reduced. Disorders of the heart’s 
electrical transport can alter cardiac output, independent of the best 
pharmacological management. Delays in electrical conduction that oc-
cur in the presence of left bundle branch block, together with increased 
overall ventricular time due to delayed activation of the left free wall, re-
sults in mechanical dyssynchrony. Equally, this can happen because of 
traditional pacemaker implantation (right atrial and ventricular stimu-
lation) with delayed activation of the left ventricle, thus generating ven-
tricular dyssynchrony with alteration of the cardiac debit. This dyssyn-
chrony does not have any systemic repercussion in normal hearts, but in 
an insufficient heart, the repercussion is significant and induces worsen-
ing of the heart failure. Cardiac resynchronization therapy by means of 
a multisite pacemaker offers pacing simultaneously in the right atrium, 
right ventricle and left ventricle. It is able to correct the dyssynchrony 
and improve both cardiac function and medical therapy. 
The objective of this systematic review was to investigate whether 
cardiac resynchronization therapy improved mortality and reduced hos-
pitalizations among patients with heart failure and low ejection fraction 
and wide QRS.
METHODS
The type of study considered for this review was randomized con-
trolled trials. The types of participants considered were patients with 
heart failure with low ejection fraction and QRS ≥ 120 msec, who 
were classified as NYHA II, III or IV. The type of intervention consid-
ered was the multisite pacemaker, in comparison with medical therapy 
or a univentricular pacemaker. The primary outcome considered was 
mortality and the secondary outcome was hospitalization due to heart 
failure.
The search strategy consisted of reviewing the databases of the Co-
chrane Library, Medical Literature Analysis and Retrieval System On-
line (Medline) and Literatura Latino-Americana e do Caribe em Ciên-
cias da Saúde (Lilacs), and cardiology congresses. The searches were re-
stricted to the period from 1990 to 2006. There were no limitations on 
language or date of publication, or other possible restrictions. 
The following keywords were accessed: “heart failure, congestive” or 
“heart failure, congestive/” or “heart failure, congestive/CO” or “heart fail-
ure, congestive/MO” or “heart failure, congestive/TH” [subject descrip-
tor] and “cardiac pacemaker, artificial” or “cardiac pacemaker, artificial/” 
or “cardiac pacemaker, artificial/AE” or “cardiac pacemaker, artificial/UT” 
[subject descriptor] and “controlled clinical trial” or “meta-analysis” or 
“multicenter study” or “randomized controlled trial” [publication type].
The methodological quality of the selected trials was assessed using 
the criteria described in the Cochrane Handbook (Handbook 2004).12
The statistical analyses were performed using the RevMan comput-
er software (Cochrane Center: available at: http://www.cochrane.org). 
Dichotomous outcomes were analyzed by calculating the relative risk 
(RR) for each trial, and the uncertainty in each result was expressed us-
ing confidence intervals (CI). When the overall results were significant, 
the number needed to treat (NNT) was calculated. The RR estimates 
were based on a random effects model (Figure 1).
RESULTS
Seven randomized trials with 3164 patients met the inclusion cri-
teria for this systematic review: Abraham et al.,13 Bristow et al.,14 Ca-
zeau et al.,15 Cleland et al.,16 Higgins et al.,17 Leclercq et al.18 and Young 
et al.19 These were all published studies. The etiology of heart failure 
was unimportant for the patients recruited, but acute ischemia, uncor-
rectable valve disorders and hypertrophic or restrictive cardiomyopathy 
were excluded from all these trials. One other trial in which the con-
trol group consisted of patients with a univentricular pacemaker was re-
stricted to patients with atrial fibrillation.20 
Abraham et al.13 Bristow et al.14 Cleland et al.16
Higgins et al.17 Leclercq et al.18 Young et al.19
Cazeau et al.15
32 studies
7 studies included
25 studies excluded 
Inclusion /exclusion criteria
Lilacs - Medline - Cochrane Library 
1990 to 2006
Figure 1. Methodological flow of search strategy.
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QRS width was a criterion for all the included trials: three trials 
specified ≥ 120 msec;14,16,17 two trials ≥ 130 msec;13,19 one trial ≥ 150 
msec;15 and one trial ≥ 200 msec.18 No trials recruited patients with an 
ejection fraction > 40%. One trial included NYHA class II.17 Bristow’s 
study14 had three arms, comparing optimal pharmacological therapy, 
cardiac resynchronization therapy and cardiac resynchronization thera-
py with cardioverter defibrillator. The follow-up for each study ranged 
from two months to 18 months. 
All of these studies had good methodological quality. However, their 
inclusion criteria and choice of control group were heterogeneous.
Mortality
This outcome was considered in three ways:
1) All-causes mortality: five studies13,14,16,17,19 presented data that were 
put into a meta-analysis that found a statistical difference favoring 
the experimental group, with an absolute risk reduction of 4%; CI: 
0.60 to 0.83; RR 0.65; and NNT 25 (Figure 2).
2) Death due to congestive heart failure: two studies14,16 presented data 
that were put into a meta-analysis that did not find any statistical dif-
ference between the groups (CI: 0.60 to 1.03; RR 0.79) (Figure 2).
3) Sudden cardiac death: three studies14,16,19 were included in a meta-
analysis that found a slight but statistically significant difference fa-
voring the experimental group, with an absolute risk reduction of 
1% (CI: 046 to 0.96; RR 0.67) (Figure 2).
Hospitalization due to heart failure
Six studies13,15-19 were put into a meta-analysis that found a reduc-
tion in the absolute risk of hospitalization of 9%, favoring the experi-
mental group (CI: 0.51 to 0.94; RR 0.69; NNT 11) (Figure 3). In this 
meta-analysis there was statistical heterogeneity, which was demonstrat-
Figure 2. Systematic review: meta-analysis on mortality.
Review: Systematic review on effectiveness of cardiac resynchronization therapy: use of multisite pacemakers
Comparison: 07 Multisite pacemaker vs Control
Outcome: 01 Mortality
Study or sub-category
Treatment 
n/N
Control 
n/N
RR (random) 
95% Cl
Weight 
%
RR (random) 
95% Cl
01 All-cause mortality
Abraham 12/220 16/225 5.10 0.74 (0.36, 1.53)
Bristow 105/595 77/308 39.78 0.71 (0.54, 0.92)
Cleland 82/409 120/404 44.81 0.67 (0.53, 0.86)
Higgins 11/245 16/245 4.82 0.69 (0.33, 1.45)
Young 14/187 15/182 5.50 0.91 (0.45, 1.83)
Subtotal (95% Cl) 1664 1364 100.00 0.70 (0.60, 0.83)
Total events: 224 (Treatment), 244 (Control)
Test for heterogeneity: Chi2 = 0.65. df = 4 (P=0.96), P = 0%
Test for overall effect: Z = 4.23 (P < 0.0001)
02 Death due to congestive heart failure
Bristow 52/595 34/308 43.79 0.79 (0.53, 1.19)
Cleland 46/409 58/404 56.21 0.78 (0.55, 1.12)
Subtotal (95% Cl) 1004 712 100.00 0.79 (0.60, 1.03)
Total events: 98 (Treatment), 92 (Control)
Test for heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97), P = 0%
Test for overall effect: Z = 1.73 (P = 0.08)
03 Sudden cardiac death
Bristow 17/595 18/308 31.99 0.49 (0.26, 0.94)
Cleland 29/409 38/404 62.67 0.75 (0.47, 1.20)
Young 3/187 3/182 5.34 0.97 (0.20, 4.76)
Subtotal (95% Cl) 1191 894 100.00 0.67 (0.46, 0.96)
Total events: 49 (Treatment), 59 (Control)
Test for heterogeneity: Chi2 = 1.37, df = 2 (P=0.50), I2 = 0%
Test for overall effect: Z = 2.18 (P = 0.03)
0,1 0,2 0,5
Favours treatment Favours control
1 2 5 10
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ed by I2 > 50% (I2
 
= 70.2%). Visually, in Figure 3, the study by Young 
et al.19 is separate from the others. We removed this study and redid the 
meta-analysis, and the statistical heterogeneity disappeared, such that 
I2 = 21.4% (Figure 4). This alteration did not modify the result from 
the meta-analysis, which continued to favor the experimental group. 
We looked for a source of clinical heterogeneity to explain this finding 
and we saw that, on the whole, the disease was more severe among the 
patients in Young’s study19 (i.e. they had an indication for an implant-
able cardiac defibrillator), with less chance of gaining the morphometric 
remodeling benefits that might be associated with cardiac resynchroni-
zation. Other secondary outcomes (quality of life, six-minute walking 
Figure 4. Systematic review: meta-analysis on hospitalization without Young’s study;19 I2 = 21.4%.
Review: Systematic review on effectiveness of cardiac resynchronization therapy: use of multisite pacemakers
Comparison: 07 Multisite pacemaker vs Control
Outcome: 02 Hospitalizations due to congestive heart failure
Study or sub-category
Treatment 
n/N
Control  
n/N
RR (random)  
95% Cl
Weight  
%
RR (random)  
95% Cl
Abraham 18/228 34/225 15.25 0.52 (0.30, 0.90)
Cazeau 3/29 9/29 3.62 0.33 (0.10, 1.11)
Cleland 125/409 184/404 55.86 0.67 (0.56, 0.80)
Higgins 32/245 39/245 21.63 0.82 (0.53, 1.26)
Leclercq 3/39 11/39 3.64 0.27 (0.08, 0.90)
Total (95% Cl) 950 942 100.00 0.64 (0.50, 0.80)
Total events: 181 (Treatment), 277 (Control)
Test for heterogeneity: Chi2 = 5.09, df = 4 (P = 0.28), I2 = 21.4%
Test for overall effect: Z = 3.79 (P = 0.0001)
0,1 0,2 0,5
Favours treatment Favours control
1 2 5 10
distance test and functional class) were analyzed in this systematic re-
view, but these merely reflected the morbidity that was more broadly ex-
pressed through the need for hospitalization.
DISCUSSION
When cardiac resynchronization therapy was added to other forms 
of medical therapy, the morbidity rate decreased, i.e. there was an effec-
tive improvement in patients’ conditions, with a 9% reduction in hos-
pitalization due to heart failure. The primary and main outcome of this 
review, i.e. mortality, was expressed in several ways: all causes, due to 
Figure 3. Systematic review: meta-analysis on hospitalization; I2 = 70.2%.
Review: Systematic review on effectiveness of cardiac resynchronization therapy: use of multisite pacemakers
Comparison: 07 Multisite pacemaker vs Control
Outcome: 02 Hospitalizations due to congestive heart failure
Study or sub-category
Treatment  
n/N
Control  
n/N
RR (random)  
95% Cl
Weight  
%
RR (random)  
95% Cl
Abrahan 18/228 34/225 15.87 0.52 (0.30, 0.90)
Cazeau 3/29 9/29 5.49 0.33 (0.10, 1.11)
Cleland 125/409 184/404 27.72 0.67 (0.56, 0.80)
Higgins 32/245 39/245 19.20 0.82 (0.53, 1.26)
Leclercq 3/39 11/39 5.52 0.27 (0.08, 0.90)
Young 85/187 78/182 26.21 1.06 (0.84, 1.33)
Total (95% Cl) 1137 1124 100.00 0.69 (0.51, 0.94)
Total events: 266 (Treatment), 355 (Control)
Test for heterogeneity: Chi2 = 16.76, df = 5 (P = 0.005), I2 = 70.2%
Test for overall effect: Z = 2.32 (P = 0.02)
0,1 0,2 0,5
Favours treatment Favours control
1 2 5 10
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heart failure and due to sudden cardiac death. Among these, mortality 
due to heart failure was the main expression of this study. However, un-
fortunately, this measurement could only be extracted from two stud-
ies, for which the meta-analysis did not show statistical significance. All-
cause mortality was extracted from five studies and showed an absolute 
risk reduction of 6% favoring the experimental group, while the other 
form of expression for mortality (sudden cardiac death) was extracted 
from three studies, and showed statistical significance for the experi-
mental group with an absolute risk reduction of 1%. 
Since the intervention proposed in this study addresses heart failure, 
it has to be inferred that heart resynchronization by means of a multi-
site pacemaker is ineffective under the circumstances presented in this 
review, with regard to modifying the progression to death. However, it 
is difficult to interpret this in daily medical practice, since sudden death 
could occur in a case of progressive heart failure without hospitalization 
that is oligosymptomatic because of excessive physical self-restriction, 
while a case of supposed progressive heart failure with hospitalization 
could be the result of significant acute electrical disturbances caused by 
drug use or non-use, among patients who were previously stable. This 
shows that biventricular stimulation improves the myocardial contrac-
tile synchrony, which consequently gives rise to hemodynamic improve-
ment but without any change to mortality. On the other hand, uni-
ventricular stimulation causes myocardial contractile dyssynchrony that 
worsens the heart failure and increases the numbers of hospitalizations. 
Our data in this systematic review on mortality are concordant with 
the data in a previous systematic review,20 which found statistically sig-
nificant data favoring the experimental group with regard to all-causes 
mortality (reduction by 21%; RR 0.79; CI: 0.66 to 0.96), but without 
statistical significance for death due to congestive heart failure (RR 0.60; 
CI: 0.36 to 1.01). For the endpoint of hospitalization due to heart fail-
ure, the meta-analysis of the previous review did not demonstrate any 
statistically significant difference for any group (CI: 0.41 to 1.12), al-
though in the results the author emphasized that they were reduced in 
the experimental group by 32%. One unpublished study was included 
in that outcome (RD-CHF21). Another study19 was put into the me-
ta-analysis of the previous review20 but with an inexplicably different 
numbers of participants: 554 in total, of which 272 in the experimental 
group and 282 in the control group (the published version of the Mir-
acle ICD study has, however 369 participants: 187 in the experimental 
group and 182 in the control group19). 
Another review conducted on four studies22 (three unpublished 
studies with data from the internet and one published study15) re-
sulted in a meta-analysis favoring multisite pacemakers for reducing 
death due to congestive heart failure (odds ratio, OR: 0.49; CI: 0.25 to 
0.93), but without statistical significance for all-causes mortality (OR 
0.77; CI: 0.51 to 1.18).
In a systematic review published in 2006,23 the meta-analysis result 
regarding the endpoints of mortality due to congestive heart failure and 
sudden death differed from ours, in that it was statistically favorable 
towards the experimental group regarding mortality due to congestive 
heart failure (OR 0.62; CI: 0.45 to 0.84), although without any statisti-
cally significant difference regarding sudden death (OR 1.04; CI: 0.73 
to 1.22). For the outcome of mortality due to congestive heart failure, 
the meta-analysis was conducted on five studies, of which two had zero 
mortality. Among the other three studies, one13 was not included in our 
meta-analysis because it did not present objective data for extraction re-
garding this endpoint. All-cause mortality was significantly reduced, by 
29% (OR 0.71; CI: 0.57 to 0.88).
Our study has potential differences with other systematic reviews 
because we only used data from studies reported in the format of jour-
nal articles. We did not use data coming from internal studies providing 
information for the pharmaceutical industry or from sources other than 
articles published in medical journals. Our systematic review did not in-
clude any data from unpublished studies. All the data from the studies 
included in this systematic review were extracted by the present authors 
from published articles, as shown by the respective references. 
CONCLUSION
The use of multisite pacemakers with cardiac resynchronization 
therapy was associated with functional improvements for patients with 
heart failure, thereby decreasing the rate of hospitalization due to heart 
failure. From the results of this systematic review, there is no evidence 
that cardiac resynchronization therapy reduces specific death due to 
congestive heart failure.
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